Nectin Therapeutics recently secured a significant $10.00M in a Venture Round investment on 06 May 2024 from GIBF Fund. The company's vision and innovative approach in the biotechnology industry make it a promising investment opportunity in the field of immunotherapy and cancer treatment.
Nectin Therapeutics
Unlocking the power of the immune system - next-generation immunotherapy
Founded 2017
Israel
12 employees
Series Unknown
Total: $46.40M
Biotechnology, Life Sciences
Israel
12 employees
Series Unknown
Total: $46.40M
Biotechnology, Life Sciences
General Information
Get notified when Nectin Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Nectin Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Israel Market
Biotechnology
About Nectin Therapeutics
Taxonomy: biotech, immunotherapy, cancer therapy, immune system, therapeutic agents, antibodies, resistance mechanisms, CAR-T, CAR-NK, targeted therapy, oncology, novel agents, immune cell, tumor targeting, drug development
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | •••••• | 1 | •••• •••• | 06 May 2024 |
| Grant | •••••• | 1 | •••• •••• | 28 Feb 2024 |
| Series A | •••••• | 3 |
|
30 Nov 2022 |
| Series A | •••••• | 1 |
|
07 Mar 2022 |
| Venture Round | •••••• | 1 |
|
14 Jul 2020 |
Nectin Therapeutics Alternatives & Competitors
Nectin Therapeutics vs
Biond Biologics Ltd
Israel
Biond - Innovative immunotherapies and a pioneering intracellular delivery for biologics for the tre...
Series C
43 employees
Biotechnology, Health Care
Nectin Therapeutics vs
Kurome Therapeutics, Inc.
United States
A preclinical stage company focused on subverting cancer's ability to evade therapy.
Series A
6 employees
Biotechnology, Health Care
Nectin Therapeutics vs
Caedo Oncology AS
Norway
We create improved treatment options for cancer patients through unique immunotherapy opportunities
Series Unknown
6 employees
Biotechnology, Health Care
FAQ About Nectin Therapeutics
Unlocking the power of the immune system - next-generation immunotherapy
Nectin Therapeutics was founded in 2017.
Nectin Therapeutics is headquartered in Israel.
Nectin Therapeutics operates in the following industries: Biotechnology, Life Sciences.
Nectin Therapeutics has approximately 12 employees.
Nectin Therapeutics has completed 6 funding rounds, raising a total of $46.40M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Nectin Therapeutics include Biond Biologics Ltd, Kurome Therapeutics, Inc., Caedo Oncology AS, Novelogics Biotechnology Inc., NextCure, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nectin Therapeutics and Biond Biologics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Don't just browse. Track.
Signal Tracker monitors Nectin Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.